Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, SGLT2i

Novo Q4 '21 London Earnings; Sanofi and Regeneron Q4 ‘21 and FY ‘21 Earnings Updates

Here is a brief preview of this blast: A series of cardiometabolic-related news items have been observed: Novo Nordisk hosted its post-Q4 '21 earnings event (see previous FENIX insight on Q4 '21 Novo earnings from February 2); and Sanofi (press release; slides; view infographic) and Regeneron (press release; slides), hosted their respective Q4 and FY '21 earnings calls. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.